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Abstract
Background: Epicardial adipose tissue (EAT) is an emerging cardio-metabolic risk factor and has been shown to
correlate with adverse cardiovascular (CV) outcome; however the underlying pathophysiology of this link is not well
understood. The aim of this study was to evaluate the relationship between EAT and a comprehensive panel
of cardiovascular risk biomarkers and pulse wave velocity (PWV) and indexed left ventricular mass (LVMI) in a
cohort of patients with cardiovascular disease (CVD) and diabetes compared to controls.
Methods: One hundred forty-five participants (mean age 63.9 ± 8.1 years; 61% male) were evaluated. All patients
underwent cardiovascular magnetic resonance (CMR) examination and PWV. EAT measurements from CMR were
performed on the 4-chamber view. Blood samples were taken and a range of CV biomarkers was evaluated.
Results: EAT measurements were significantly higher in the groups with CVD, with or without T2DM compared
to patients without CVD or T2DM (group 1 EAT 15.9 ± 5.5 cm2 vs. group 4 EAT 11.8 ± 4.1 cm2, p = 0.001; group 3
EAT 15.1 ± 4.3 cm2 vs. group 4 EAT 11.8 ± 4.1 cm2, p = 0.024). EAT was independently associated with IL-6 (beta 0.
2, p = 0.019). When added to clinical variables, both EAT (beta 0.16, p = 0.035) and IL-6 (beta 0.26, p = 0.003) were
independently associated with PWV. EAT was significantly associated with LVMI in a univariable analysis but not
when added to significant clinical variables.
Conclusions: In patients with cardio-metabolic disease, EAT was independently associated with PWV. EAT may be
associated with CVD risk due to an increase in systemic vascular inflammation. Whether targeting EAT may
reduce inflammation and/or cardiovascular risk should be evaluated in prospective studies.
Keywords: Epicardial adipose tissue, Pulse wave velocity, Arterial stiffness, Cardiovascular magnetic resonance, Left
ventricular mass, Type 2 diabetes mellitus
Background
The distribution of body fat appears to be important in
cardiovascular disease (CVD) risk [1]. With recent ad-
vances in imaging techniques, attention has focussed on
ectopic visceral fat distribution including the fat around
the heart, known as epicardial adipose tissue (EAT). This
interest is underpinned by population cohort studies that
reported the association between EAT and adverse CV
outcome [2, 3]. EAT is a metabolically active visceral
and perivascular fat depot, surrounding the myocardium
and coronary arteries with no separating fascia. Under
pathologic circumstances, EAT can act both locally or by
paracrine secretion of mediators including adipokines,
inflammatory cytokines, or reactive oxidative species
that can potentially adversely affect the adjacent coron-
ary vessels and myocardium [4]. Local secretion of bio-
active molecules by the EAT has been implicated in the
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formation of atherosclerotic plaques on the adjacent cor-
onary arteries [5–8]. The local effects of these bioactive
molecules on the neighbouring myocardium have also
been linked to atrial remodelling in atrial fibrillation
(AF) [9]. It is noteworthy that the effects of EAT on left
ventricular remodelling such as left ventricular hyper-
trophy is less well studied.
Recent studies have shown that EAT is related to ath-
erosclerotic disease in other vascular beds. In the popu-
lation based Rotterdam Study, EAT was associated with
multiple vessel beds and was independent of CV risk
factors [10]. This observation may imply endocrine sys-
temic effects of EAT [4]. EAT is metabolically active, se-
creting numerous substances associated with CVD such
as TNFα, IL-6 and IL-1β [11] that may suggest a sys-
temic effect of EAT mediated via metabolic and inflam-
matory pathways. Exploring this link might help to
provide a better understanding of the mechanism by
which EAT is associated with CVD. Tentative supportive
evidence of a systemic effect of EAT is provided by the
association between EAT and arterial stiffness, a known
predictor of adverse CV outcome [12]. Previous studies
have demonstrated an independent association between
EAT and arterial stiffness in various groups of patients
with CVD risk [13, 14]. However, this relationship has
not been studied in patients with cardio-metabolic dis-
ease and as yet the mechanism by which EAT and arter-
ial stiffness are linked is poorly understood. The
relationship between EAT and left ventricular hyper-
trophy in patients with cardio-metabolic disease has also
not been studied.
The aim of this study was to assess the association be-
tween EAT, metabolic and inflammatory biomarkers,
peripheral arterial stiffness (as measured by PWV) and
left ventricular mass (LVM) in a cohort of patients with
a spectrum of cardio-metabolic disease compared to
controls to provide an understanding of the underlying
local and systemic pathophysiological process by which
EAT might lead to adverse CVD outcome.
Methods
Study participants
This study was a single centre observational cross sec-
tional sub-study of the multicentre SUMMIT (SUrrogate
markers for Micro- and Macrovascular hard endpoints for
Innovative diabetes Tools) study. Recruitment strategy
and the imaging protocol have been described in detail
previously [15]. In summary, 145 volunteers were re-
cruited from the community, completed the imaging part
of the SUMMIT study and were included for analysis in
this study. These volunteers were categorised into one of
four groups: Group 1 comprised of type 2 diabetes melli-
tus patients (T2DM) with clinical CVD including cerebro-
vascular disease, CAD and/or lower extremity arterial
disease (LEAD); Group 2 included volunteers with T2DM
and no clinical evidence of CVD; Group 3 included sub-
jects with clinical evidence of CVD and no T2DM; and
Group 4 was a group in whom there was no clinical evi-
dence of either T2DM or CVD. To be included in either
of the T2DM groups there had to be a diagnosis of T2DM
made after the age of 35 years with no requirement for in-
sulin in the 12 months following the diagnosis. Absence of
T2DM in Groups 3 and 4 was determined via testing of
haemoglobin A1C (HbA1C) levels, and defined as a level
of less than 6.5% (48 mmol/ml). Volunteers were excluded
from the study if they had a contraindication to MRI, im-
paired renal function (eGFR < 30 ml/min/1.73m2), and
therapy for any chronic inflammatory disease or malig-
nancy. The study protocols were approved by The East of
Scotland Research Ethics Committee, and were conducted
in accordance with the Declaration of Helsinki. All volun-
teers who participated in this study provided written in-
formed consent. Informed consent was obtained from
each patient and the study protocol conformed to the eth-
ical guidelines of the 1975 Declaration of Helsinki.
Cardiovascular magnetic resonance protocols
Cardiovascular magnetic resonance (CMR) images were
acquired on a 32 RF receiver channel, 3.0 T Tesla MRI
scanner (Magnetom Trio, Siemens, Erlangen, Germany).
Full details of the CMR protocol and intra-observer re-
producibility of LV analysis in this cohort have been as
previously described in detail [15].
Epicardial adipose tissue quantification
EAT area was defined as the fat located between the
outer wall of the myocardium and the visceral layer of
the pericardium [16]. We chose a single cine four-
chamber view of each patient for EAT quantification (in
cm2) after a careful examination of the cine 4 chamber
view image to outline the fat at the end-diastolic image
as described in other studies [17–19]. EAT image ana-
lysis was carried out off-line using Segment (version 1.9,
http://segment.heiberg.se) [20]. A representative example
is shown in Fig. 1. Measurements were obtained using a
TrueFISP electrocardiogram-gated cine four-chamber
view during the end diastolic phase of the cardiac cycle
and EAT was delineated using the freehand region of
interest tool (Fig. 1). Measurement of EAT was per-
formed with the analyser (SAT) blinded to both CVD
and DM status. EAT was measured by two independent
observers (SAT and JMW) in 20% of the studies (n = 29)
selected at random to assess inter-observer variability.
Pulse wave velocity measurements
Arterial stiffness was assessed by calculating PWV using
a Sphygmocor device (Atcor Medical, West Ryde,
Australia) as described previously [21]. In brief, carotid-
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femoral PWV (measured in m/s) was calculated as the dif-
ference in time between the R wave of the ECG and the
foot of the pulse curve at the carotid and femoral arteries,
divided by the proximal distance (carotid to the fossa jug-
ulars) subtracted from the distal distance (fossa jugulars to
femoral artery measured via the umbilicus). Blood pres-
sure was measured three times via a cuff attached to the
left arm and the mean of the last two measurements re-
corded only after the patient relaxed for 5 min.
Biomarkers
Fifty-one biomarkers were analysed by the Proximity Ex-
tension Assay technique using the Proseek Multiplex
CVD96*96 reagent kit (Olink Bioscience, Uppsala,
Sweden) at the Clinical Biomarkers Facility, Science for
Life Laboratory, Uppsala. The full list of biomarkers
measured is shown in Additional file 1: Table S1.
Statistical analysis
All analyses were performed using SPSS (version 21.0,
SPSS Inc. Chicago, IL, USA). Continuous variables are
shown as mean ± standard deviation. Categorical variables
are reported as number with percentage in brackets. To
compare the four groups, ANOVA was applied as a para-
metric test with post-hoc Bonferroni correction to account
for multiple testing. In the investigation of associations
among continuous variables, a Pearson correlation test was
used for parametric data and a Spearman test for non-
parametric data. Univariate and multivariable linear regres-
sions were used for determining factors associated with
EAT and PWV and LVM. Firstly, linear regression was per-
formed to determine the association between biomarkers
and EAT and PWV and LVM. Then, regression was per-
formed to determine the independent association between
clinical variables and EAT with PWV and LVM. Finally,
biomarkers were added to the clinical variables and EAT to
determine their association with PWV and LVM. To build
the multivariable models, significant baseline clinical vari-
ables were first included. Following this, EAT and signifi-
cant biomarkers were added to significant clinical variables
in order to build a final multivariable model for association
with PWV and LVMI. For all tests a p < 0.05 was consid-
ered statistically significant.
Results
Baseline characteristics
In total 145 participants were included in study. Full
demographic details are shown in Table 1. Eighty-nine
patients (61%) were male and the mean age of the whole
cohort was 64.0 ± 8.1 years. Patients with DM had a sig-
nificantly higher BMI, HDL cholesterol and HbA1c than
those in group with neither DM nor CVD. CVD patients
were significantly older than those without CVD. Pa-
tients without CVD or DM were significantly less likely
to be male, have a history of hypertension, to be taking a
statin and had a lower LDL-cholesterol than those in
other groups. There was no significant difference in
smoking prevalence or systolic blood pressure in all four
groups. Patients with overt CVD were significantly more
likely to be taking an ACE inhibitor and beta-blocker.
Relationship between epicardial adipose tissue, LV
measurements and pulse wave velocity
PWV, EAT and LV measurements are presented in Table 1.
Inter-observer variability for EAT was good (intra-class
correlation coefficient of absolute agreement definition =
0.796). EAT measurements were significantly higher in the
groups with CVD, with or without T2DM compared to pa-
tients without CVD or T2DM (group 1 EAT 15.9 ±
5.5 cm2 vs. group 4 EAT 11.8 ± 4.1 cm2, p = 0.001; group 3
EAT 15.1 ± 4.3 cm2 vs. group 4 EAT 11.8 ± 4.1 cm2, p =
0.024). A significant correlation was found between EAT
and PWV (r = 0.28, p = 0.002). LVMI was also significantly
higher in group 1 compared to group 4 (group 1 LVMI
Fig. 1 Cardiovascular Magnetic Resonance Assessment of Epicardial Adipose Tissue. EAT was assessed on CMR cine images shown in this example. A
– a patient in group 1 (type 2 diabetes and overt CV disease) with EAT measuring 26.7cm2. B – a patient in group 4 (no diabetes or overt CV disease
with EAT measuring 10.6cm2
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61.7 ± 9.8 g/m2 vs. group 4 LVMI 52.5 ± 8.4 g/m2, p =
0.002). There was no significant difference in PWV
amongst any of the four groups.
Relationship between epicardial adipose tissue and blood
biomarkers
The full list of 51 CV biomarkers evaluated is reported
in Additional file 1: Table S1. Of these biomarkers, we
found two that were significantly correlated with both
EAT and PWV in univariate analysis (CD40L and IL-6).
There were no biomarkers that were significantly corre-
lated with both EAT and LVM. In multivariable linear
regression analysis of biomarkers, both IL-6 and CD40L
remained significantly associated with PWV (IL-6: beta
0.26, p = 0.003) (CD40L: beta − 0.21 p = 0.014) (Table 2).
In a univariate regression analysis, IL6 and CD40L were
significantly associated with EAT (IL6: beta 0.2 p =
0.019; CD40L: beta − 0.21 p = 0.01) (Additional file 1:
Table 1 Baseline Demographics, Pulse Wave Velocity and Cardiovascular Magnetic Resonance Parameters
Variable Group 1 CVD
and DM (n = 34)
Group 2 No CVD
with DM (n = 54)
Group 3 CVD without
DM (n = 28)
Group 4 No CVD
or DM (n = 29)
p value
Male 28 (82.4)* o 29 (53.7) 20 (71.4) 12 (41.4) 0.003
Age (years) 64.6 ± 6.6 62.4 ± 8.1+ 67.6 ± 8.6 62.1 ± 8.0 0.022
BMI (kg/m2) 31.0 ± 4.2* 31.0 ± 4.6* 29.2 ± 3.6 27.9 ± 3.7 0.007
Diabetes duration (years) 10.3 ± 4.8 9.0 ± 6.2 N/A N/A 0.33
Current/Ex-smoker 25 (73.5) 27 (50.0) 16 (57.1) 15 (51.7) 0.16
Hypertension 27 (79.4)* 34 (63.0)* 24 (85.7)* 7 (24.1) < 0.001
Stroke 5 (14.7)*o 0 (0) 2 (7.1) 0 (0) 0.008
LEAD 9 (26.5)* o 0 (0) 5 (17.9) o 0 (0) < 0.001
CAD 25 (73.5)* 0 (0) 22 (78.6)*o 0 (0) 0.001
Atrial Fibrillation 1 (2.9) 1 (1.9) 1 (3.6) 2 (6.9) 0.69
ACE Inhibitor 21 (61.8)*o 17 (30.4) 15 (53.6)* 3 (10.3) < 0.001
Beta Blocker 15 (44.1)*o 6 (11.1) 12 (42.9)*o 1 (3.4) < 0.001
Statin 30 (88.2)* 39 (72.2)* 22 (78.6)* 7 (24.1) < 0.001
Systolic BP (mmHg) 126.3 ± 12.5 134.0 ± 14.2 130.7 ± 13.6 132.7 ± 19.1 0.13
Diastolic BP (mmHg) 73.2 ± 7.1*o 78.0 ± 7.4 75.5 ± 8.5 81.0 ± 9.0 0.001
Total Cholesterol (mmol/l) 3.7 ± 0.8* 4.0 ± 0.8* 4.0 ± 0.7* 5.1 ± 0.9 < 0.001
LDL Cholesterol (mmol/l) 1.7 ± 0.5* 2.0 ± 0.8* 2.0 ± 0.6* 2.8 ± 0.8 < 0.001
HDL Cholesterol (mmol/l) 1.1 ± 0.3* 1.3 ± 0.3* 1.3 ± 0.5 1.5 ± 0.4 < 0.001
Triglycerides (mmol/l) 2.1 ± 1.0+ 1.7 ± 0.8 1.5 ± 0.8 1.7 ± 1.0 0.06
Serum Creatinine (μmol/l) 84.4 ± 22.6*o 73.3 ± 17.3 82.5 ± 19.1 70.6 ± 15.3 0.006
HbA1c (mmol/l) 7.5 ± 1.1*+ 7.2 ± 1.1*+ 5.5 ± 0.2 5.6 ± 0.2 < 0.001
PWV (m/s) 11.4 ± 3.0 11.1 ± 2.7 11.1 ± 2.4 9.9 ± 2.4 0.12
EAT (cm2) 15.9 ± 5.5* 13.5 ± 3.5 15.1 ± 4.3* 11.8 ± 4.1 0.001
LVMI (g/m2) 61.7 ± 9.8* 55.5 ± 10.6 59.8 ± 10.0* 52.5 ± 8.4 0.001
LVEF (%) 64.6 ± 10.5 65.9 ± 8.9 64.6 ± 10.6 66.0 ± 7.4 0.86
LVEDVI (ml/m2) 70.6 ± 12.4 67.0 ± 12.9+ 75.5 ± 20.4 68.7 ± 9.9 0.07
LVESVI (ml/m2) 25.4 ± 9.8 23.2 ± 9.0 28.0 ± 16.4 23.5 ± 6.7 0.24
LGE (%) 9 (26.5) 3 (5.6) 11 (39.3) 0 (0) < 0.001
BMI body mass index; BP blood pressure; CAD coronary artery disease, LEAD lower extremity arterial disease; ACE angiotensin converting enzyme;
ARB angiotensin II receptor blocker; PWV pulse wave velocity; LVM left ventricular mass index; LVEF left ventricular ejection fraction; LVEDV left
ventricular end diastolic volume; LVESV left ventricular end systolic volume; SV stroke volume; LGE late gadolinium enhancement
Categorical data presented as number (percentage), continuous data presented as mean ± SD
*p < 0.05 vs. group 4 (no DM or CVD); +p < 0.05 vs. group 3 (CVD without DM); op < 0.05 vs. group 2 (DM without CVD)
Figures in bold p < 0.05
Table 2 Multivariable Linear Regression of PWV and Biomarkers
PWV (m/s)
β 95% CI β (S) p value
CD40L −0.5 −0.90- -0.10 − 0.21 0.014
IL-6 0.67 0.23–0.1.12 0.26 0.003
PWV pulse wave velocity; CD40L CD40 ligand; IL-6 interleukin-6
All biomarkers significantly associated with EAT and PWV in univariate analysis
(Additional file 1: Table S1) were included in multivariable analysis
Figures in bold p < 0.05
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Figure S1). IL-6 was significantly higher in Group 1
compared to group 4 (group 1–5.9 ± 1.3 pg/ml group 4–
4.8 ± 0.7 pg/ml p < 0.001).
Factors associated with pulse wave velocity
In univariate analysis for association with PWV we found
that age, systolic blood pressure, history of smoking, lower
extremity arterial disease, AF and EAT were all signifi-
cantly associated with PWV (Additional file 1: Table S2).
In a model with only significant clinical variables included,
age (beta 0.32 p < 0.001), systolic BP (beta 0.34, p < 0.001)
and lower extremity arterial disease (LEAD) (beta 0.17 p
= 0.025) remained significantly associated with PWV
(Table 3). When added to clinical variables, EAT remained
associated with PWV (beta 0.12 p = 0.026). Finally, when
IL-6 and CD40L were added to the model both EAT (beta
0.16 p = 0.035) and IL-6 (beta 0.20 p = 0.005) remained in-
dependently associated with PWV in addition to age and
systolic blood pressure however CD40L was not. The
stepwise additions of both EAT and IL-6 added significant
independent power to model association with PWV.
Factors associated with left ventricular mass
In univariable analysis there were several significant clin-
ical variables associated with LVMI, (Additional file 1:
Table S2). EAT was also significantly associated with
LVMI in univariate analysis (beta 0.33, p = 0.002). In
multivariable analysis, only male gender and history of
hypertension remained significantly associated with
LVMI (Additional file 1: Table S3). When added to sig-
nificant clinical variables EAT was no longer significantly
associated with LVMI (beta 0.07, p = 0.33).
Discussion
In this study we identified several novel findings. First,
we have shown that patients with overt cardio-metabolic
disease have significantly more EAT than those without.
Second, we have shown that EAT is significantly
associated with PWV, a marker of arterial stiffness that
is linked to adverse CVD outcome. We did not, however,
find any significant association between EAT and LVM.
Finally, we have shown, to the best of our knowledge,
for the first time, a clear association between EAT and
IL-6, a biomarker associated with vascular inflammation,
and that both EAT and IL-6 are significantly independ-
ently associated with PWV even when baseline clinical
characteristics are accounted for and have incremental
association PWV when added to clinical variables.
Arterial stiffness measured by PWV has been associated
with an increased risk of CVD in a wide range of patients
and has been found to be an independent predictor of
major adverse CV events [12]. Furthermore, it has also
been shown to have incremental additional prognostic
value when used in combination with traditional risk pre-
dictors such as blood pressure and cholesterol [22]. Our
finding that EAT is a significantly independently associ-
ated with arterial stiffness as measured by PWV is consist-
ent with previous studies that showed that EAT, measured
by echocardiography, was independently associated with
endothelial function measured by PWV [23]. In a study of
100 patients with biopsy-proven non-alcoholic fatty liver
disease (NAFLD), a condition associated with inflamma-
tion and atherosclerosis, the authors found that epicardial
adipose thickness was significantly higher NAFLD patients
compared to controls and was a significant independent
predictor of PWV [24]. Our study extends the results of
this study to patients with cardio-metabolic disease by
assessing patients with CMR (the gold-standard). In our
study, the availability of a comprehensive panel of bio-
markers may help provide a mechanistic understanding
for these observations.
Prior studies have demonstrated that inflammation, oxi-
dative stress, and visceral fat volume predispose to CVD
[1, 25]. There have been several studies examining the link
between pericardial adipose and CVD. In a study of over
6000 patients from the MESA cohort the authors found
Table 3 Multivariable associations with pulse wave velocity
Clinical Clinical + EAT Clinical + EAT + Biomarkers
β 95% CI β (S) p value β 95% CI β (S) p value β 95% CI β (S) p value
Age 0.11 0.07–0.16 0.36 < 0.001 0.10 0.06–0.15 0.32 < 0.001 0.10 0.05–0.15 0.31 < 0.001
Systolic BP 0.06 0.04–0.09 0.37 < 0.001 0.07 0.04–0.09 0.37 < 0.001 0.07 0.04–0.09 0.39 < 0.001
LEAD 1.60 0.21–2.98 0.17 0.025 1.47 0.11–2.84 0.15 0.035 1.30 −0.04-2.65 0.14 0.06
Atrial fibrillation 2.03 −0.11 -4.16 0.14 0.06
EAT 0.10 0.01–0.19 0.17 0.026 0.10 0.01–0.19 0.16 0.03
IL-6 0.53 0.16–0.90 0.20 0.005
CD40L −0.03 −0.37-0.31 −0.01 0.86
Chi-Square 0.613 0.634* 0.658^
BP blood pressure; LEAD lower extremity arterial disease; EAT epicardial adipose tissue; IL-6 interleukin 6, CD40L CD40 ligand, (S) standardized
*p 0.026 vs. clinical; ^p = 0.011 vs. clinical + EAT
Figures in bold p < 0.05
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that pericardial adipose volume had a significant positive
association with IL-6, and also had a borderline signifi-
cance for CVD outcomes after adjustment for traditional
risk factors [26]. More specifically, pericardial adipose also
predicted incident coronary heart disease in a subset of
these patients [27]. Finally, in a large cohort of over 1000
patients from the Framingham study, Tadros et al. re-
ported an association between pericardial fat and inflam-
matory biomarkers including IL-6 [28].
More recent work has suggested that EAT is associated
with systemic inflammation. A meta-analysis of 40 gene ex-
pression studies on EAT suggested that EAT might well
mediate its effects on CVD through IL6 [29]. These obser-
vations lend support to the increasing recognition that EAT
is a metabolically active endocrine organ and a source of
pro-inflammatory adipokines that have significant impact
on remote vascular tissues [30]. The findings of our study
lend support to this. In our study IL-6, an inflammation
mediator, was strongly associated with both EAT and with
PWV. It is noteworthy that IL-6 is capable of inducing vas-
cular smooth muscle proliferation that can lead to endothe-
lial dysfunction and arterial stiffness [31]. In our study, we
observed an incremental independent association of both
EAT and IL-6 with PWV shown, for the first time, in our
study. Indeed, further supporting our inflammatory theory
is the association with CD40L, although this did not remain
significant when included in the multivariable model.
CD40L has also been associated with cardio-metabolic dis-
ease and is known to be released by adipose tissue [32, 33].
Obviously, any indication that the observed relationship be-
tween EAT and PWV are due to the effects of IL-6 remains
purely speculative and cannot be inferred directly from this
observational study. Additionally, the fact that EAT was still
independently associated with PWV even when IL-6 was
added to the model might suggest that there may be other
pathways which need to be further elucidated by which
EAT is associated with increased PWV.
In our study we found that although EAT was associated
with LVM in a univariate analysis, it was not significant in
multivariable analysis. Prior studies using echocardiog-
raphy have reported differing results regarding the rela-
tionship between EAT and LVM. Fosshaug et al. evaluated
60 heart failure patients and found that EAT was related
to LVM [34]. These results were replicated in a more re-
cent study using PET-CT by Bakkum et al. in over 200
obese patients without significant CAD [35]. Both of these
studies contrast the study by Gates et al. in 119 healthy
males suggesting that overall body fat was linked to LVM
rather than EAT [36]. Our study differs from all of these
studies by using CMR, the gold-standard for assessment
of LVMI. Additionally, our study is also, to the best of our
knowledge, the first to include patients with CVD and
T2D disease rather than just healthy volunteers. Because
of this, there may however have been confounding of
LVM based on medication use such as ACE inhibitors. It
may however be the case that LVM is not influenced by
local adipose but rather by overall adiposity and BMI. A
large study from the Framingham cohort found that while
pericardial adipose was associated with LVM in univari-
able analysis, this association was no longer significant
once adjusted for body weight or visceral adipose [37].
Limitations
As our findings come from a single-center study, these
findings require confirmation within a larger multi-center
setting. Due to the nature of recruitment of these patients
in which the full biomarker panel was only available in a
single centre, the number of patients for analysis is rela-
tively small, although this is one of the largest papers to
examine EAT, PWV and such a comprehensive panel of
biomarkers using CMR. Additionally as a cross-sectional
study causality cannot be proven and only associations can
be made. Although we feel that our selection of 51 bio-
markers is both pragmatic and broadly covers most patho-
physiologcally important biomarkers, we cannot completely
exclude the possibility that there may be other biomarkers
which could be important, for example adiponectin. Finally,
we only performed measurement of EAT in the 4-chamber
view. Theoretically 3-dimensional measurement of EAT
may have provided different results, however we wished to
perform a protocol that was simple to utilise and not too
time-consuming for practicing clinicians. However, meas-
urement of adipose in the 4-chamber view has shown ex-
cellent correlation with 3-dimensional quantification in
several other studies [17–19]. Despite these limitations, we
believe our findings are of potential importance and can be
seen as hypothesis-generating.
Conclusions
EAT is gaining prominence as a non-invasive biomarker
which might be associated with adverse CV outcome, how-
ever the mechanism by which it does so remains unclear.
We performed a study in patients in both controls and pa-
tients with type 2 diabetes and/or overt cardiovascular dis-
ease evaluating EAT measured by CMR and examined its
relations with established CV biomarkers, arterial stiffness
measured by PWV and left ventricular mass. EAT was sig-
nificantly increased in patients with overt cardio-metabolic
disease compared to those without and was independently
associated with arterial stiffness measured by pulse wave
velocity. EAT was significantly associated with increased
markers of systemic inflammation (IL-6) and both EAT and
IL-6 were significantly associated with PWV independent
of clinical variables, suggesting potential inflammatory
pathophysiological link. Additionally, both EAT and IL-6
had significant incremental association with PWV. EAT
may be associated with systemic inflammation and could
be a therapeutic target in cardio-metabolic disease.
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Additional file
Additional file 1: Table S1. Correlations between cardiovascular
biomarkers and epicardial adipose tissue (EAT), pulse wave velocity (PWV)
and left ventricular mass index (LVMI). Table S2. Univariable Linear
Regression of Clinical Variables and EAT with Pulse Wave Velocity and LV
Mass Index. Table S3. Multivariable Associations with LV Mass Index.
Figure S1. Correlations between EAT, IL-6 and CD40L. (DOCX 88 kb)
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